Talha Badar, Hematology/Oncology specialist at Mayo Clinic, shared an article by Jing Lu, et al. on X:
“Venetoclax and Decitabine vs Intensive Chemotherapy as Induction for Young Patients with Newly Diagnosed AML.
Venetoclax plus decitabine NOT INFERIOR to intensive chemo in young fit AML.
VEN+DEC was well tolerated.”
Venetoclax and Decitabine vs Intensive Chemotherapy as Induction for Young Patients with Newly Diagnosed AML.
Authors: Jing Lu, et al.
